NCT07142707View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

PHASE1RecruitingINTERVENTIONAL

Enrollment

64

Participants

Timeline

Start Date

September 3, 2025

Primary Completion Date

May 30, 2026

Study Completion Date

May 30, 2026

Conditions

Obesity

Interventions

DRUG

MBX 4291

MBX 4291 will be administered subcutaneously (SC)

DRUG

Placebo

Placebo: Placebo will be administered subcutaneously (SC)

Trial Locations (1)

37920

RECRUITING

MBX Biosciences Investigational Site, Knoxville

Sponsors

Lead Sponsor

MBX Biosciences

All Listed Sponsors

lead

MBX Biosciences

INDUSTRY